4.2 Tirzepatide in weight regulation and metabolic improvement Obesity is one of the major risk factors for OSAS, and weight reduction has been associated with improvements in OSAS-related symptoms
Patients should always follow the instructions provided by their healthcare provider and pharmacy
PlexusDx works with licensed 503A compounding pharmacies to ensure precision dosing tailored to your body's GLP-1 receptor sensitivity and weight loss goals
A study published in Diabetes, Obesity and Metabolism (Frias et al., 2021) from an early phase 2 comparison found that tirzepatide produced dose-dependent weight loss that exceeded semaglutide 1 mg across all dose levels tested, confirming the advantage of the dual mechanism
FIGURE 4 2.3.1 Cytokine reduction Besides the glucose homeostasis controlling function of GLP-1RAs, its cytokine-reducing ability is gradually recognized, and thus, its potential therapeutic effect on eye diseases is starting to gain attention
